Brian Posner Biography and Net Worth

Director of Biogen

Brian S. Posner is an Independent Director of Biogen Inc. Mr. Posner has been a private investor since March 2008 and is the founder and Managing Partner of Point Rider Group LLC, a boutique consulting and advisory services firm that provides customized solutions to senior executives and boards of financial, bio-pharmaceutical and other services-related companies, as well as strategic investors that make, direct and control investments in those sectors. From 2005 to March 2008 Mr. Posner served as the President, Chief Executive Officer and co-Chief Investment Officer of ClearBridge Advisors LLC, an asset management company and a wholly-owned subsidiary of Legg Mason. Prior to that, Mr. Posner co-founded Hygrove Partners LLC, a private investment fund, in 2000 and served as its Managing Partner for five years. He served as a portfolio manager and an analyst at Fidelity Investments, a financial services company, from 1987 to 1996 and, from 1997 to 1999, at Warburg Pincus Asset Management/Credit Suisse Asset Management where he also served as co-Chief Investment Officer and Director of Research. Mr. Posner also serves as a director of AQR Funds, an investment fund, and Arch Capital Group Ltd., a specialty insurance and reinsurance provider.

What is Brian S. Posner's net worth?: The estimated net worth of Brian S. Posner is at least $766,040.00 as of October 28th, 2022. Mr. Posner owns 4,000 shares of Biogen stock worth more than $766,040 as of April 18th. This net worth evaluation does not reflect any other assets that Mr. Posner may own. Learn More about Brian S. Posner's net worth.
How do I contact Brian S. Posner?: The corporate mailing address for Mr. Posner and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at [email protected]. Learn More on Brian S. Posner's contact information.
Has Brian S. Posner been buying or selling shares of Biogen?: Brian S. Posner has not been actively trading shares of Biogen during the last ninety days. Most recently, Brian S. Posner sold 360 shares of the business's stock in a transaction on Friday, June 4th. The shares were sold at an average price of $274.17, for a transaction totalling $98,701.20. Following the completion of the sale, the director now directly owns 7,400 shares of the company's stock, valued at $2,028,858. Learn More on Brian S. Posner's trading history.
Who are Biogen's active insiders?: Biogen's insider roster includes Susan Alexander (EVP), Brian Posner (Director), Alfred Sandrock (insider), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.
Are insiders buying or selling shares of Biogen?: During the last twelve months, Biogen insiders bought shares 1 times. They purchased a total of 455 shares worth more than $101,255.70. During the last twelve months, insiders at the biotechnology company sold shares 8 times. They sold a total of 4,185 shares worth more than $1,172,646.90. The most recent insider tranaction occured on April, 2nd when insider Priya Singhal sold 93 shares worth more than $19,817.37. Insiders at Biogen own 0.6% of the company. Learn More about insider trades at Biogen.
Information on this page was last updated on 4/2/2024.

Brian S. Posner Insider Trading History at Biogen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/4/2021	Sell	360	$274.17	$98,701.20	7,400
12/2/2019	Sell	1,055	$292.35	$308,429.25	6,995
6/9/2017	Sell	1,084	$256.31	$277,840.04	6,330
6/11/2013	Sell	2,020	$219.62	$443,632.40

Brian S. Posner Buying and Selling Activity at Biogen

Biogen Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $190.52

$189.52

$192.55

50 Day Range

MA: $217.16

$192.16

$244.74

2 Week Range

Now: $190.52

$189.52

$319.76

Volume

1,512,005 shs

Average Volume

1,156,184 shs

Market Capitalization

$27.69 billion

P/E Ratio

23.87

Dividend Yield

N/A

Beta

N/A

AI “wealth window” is closing soon!

From Paradigm Press | Ad

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…